In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 6, 2000, Pages 1485-1493

  Situ, Hongsa ^a   Bobek, Libuse A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMPHOTERICIN B; HISTATIN; MUCIN; TRYPAN BLUE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CRYPTOCOCCUS NEOFORMANS; CYTOTOXICITY; GENE; HEMOLYSIS; HUMAN; HUMAN CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SALIVA;

AMINO ACID SEQUENCE; ANTIFUNGAL AGENTS; FUNGI; HUMANS; MOLECULAR SEQUENCE DATA; MUCINS; PEPTIDE FRAGMENTS; SALIVARY PROTEINS;

EID: 0034128892     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.6.1485-1493.2000     Document Type: Article

References (26)

1. Alexander, B. D., and J. R. Perfect. 1997. Antifungal resistance trends towards the year 2000. Drugs 54:657-678.
2. Biesbrock, A. R., M. S. Reddy, and M. J. Levine. 1991. Interaction of a salivary mucin-secretory immunoglobulin A complex with mucosal pathogens. Infect. Immun. 59:3492-3497.
3. Bobek, L. A., H. Tsai, A. R. Biesbrock, and M. J. Levine. 1993. Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7). J. Biol. Chem. 268:20563-20569.
4. Chavira, R., Jr., T. J. Burnett, and J. H. Hageman. 1984 Assaying proteinases with azocoll. Anal. Biochem. 136:446-450.
5. Gururaja, T. L., J. H. Levine, D. T. Tran, G. A. Naganagowda, K. Ramalingam, N. Ramasubbu, and M. J. Levine. 1999. Candidacidal activity prompted by N-terminus histatin-like domain of human salivary mucin (MUC7). Biochim. Biophys. Acta 1431:107-119.
6. Helmerhorst, E. J., P. Breeuwer, W. van't Hof, E. Walgreen-Weterings, L. C. Oomen, E. C. Veerman, A. V. Amerongen, and T. Abee. 1999. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J. Biol. Chem. 274:7286-7291.
7. Helmerhorst, E. J., I. M. Reijnders, W. Van't Hof, I. Simmons-Smit, E. C. I. Veerman, and A. V. Nieuw Amerongen. 1999. Amphotericin B-and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob. Agents Chemottier. 43:703-704.
8. Iontcheva, I., F. G. Oppenheim, and R. E. Troxler. 1997. Human salivary mucin MG1 selectively forms heterotypic complexes with amylase, proline-rich proteins, statherin, and histatins. J. Dent. Res. 76:734-743.
9. Joly, V., J. Bolard, and P. Yeni. 1992. In vitro models for studying toxicity of antifungal agents. Antimicrob. Agents Chemother. 36:1799-1804.
10. Kirsch, D. R., M. H. Lai, and J. O'Sullivan. 1988. Isolation of the gene for cytochrome P450L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Gene 68:229-237.
11. Koshlukova, S. E., T. L. Lloyd, M. W. Araujo, and M. Edgerton. 1999. Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death. J. Biol. Chem. 274:18872-18879.
12. Levine, M. J. 1993. Development of artificial salivas. Crit. Rev. Oral Biol. Med. 4:270-286.
13. Levine, M. J., M. S. Reddy, L. A. Tabak, R. E. Loomis, E. J. Bergey, P. C. Jones, R. E. Cohen, M. W. Stinson, and I. Al-Hashimi. 1987. Structural aspects of salivary glycoproteins. J. Dent. Res. 66:436-441.
14. Prakobphol, A., M. J. Levine, L. A. Tabak, and M. S. Reddy. 1982. Purification of a low-molecular-weight, mucin-type glycoprotein from human submandibular-sublingual saliva. Carbohydr. Res. 108:111-122.
15. Situ, H., H. Tsai, and L. A. Bobek. 1999. Construction and characterization of human salivary histatin-5 multimers. J. Dent. Res. 78:690-698.
16. Smith, C. M., and A. M. Reynard. 1992. Textbook of pharmacology. The W. B. Saunders Company, Philadelphia, Pa.
17. Tsai, H., and L. A. Bobek. 1997. Studies of the mechanism of human salivary histatin-5 candidacidal activity with histatin-5 variants and azole-sensitive and -resistant Candida species. Antimicrob. Agents Chemother. 41:2224-2228.
18. Tsai, H., and L. A. Bobek. 1997. Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans. Biochim. Biophys. Acta 1336:367-369.
19. Tsai, H., and L. A. Bobek. 1998. Human salivary histatins: promising antifungal therapeutic agents. Crit. Rev. Oral Biol. Med. 9:480-497.
20. Tsai, H., P. A. Raj, and L. A. Bobek. 1996. Candidacidal activity of recombinant human salivary histatin-5 and variants. Infect. Immun. 64:5000-5007.
21. Vanden Bossche, H., F. Dromer, I. Improvisi, M. Lozano-Chiu, J. H. Rex, and D. Sanglard. 1998. Antifungal drug resistance in pathogenic fungi. Med. Mycol. 36(Suppl. 1):119-128.
22. Vanden Bossche, H., G. Willemsens, and P. Marichal. 1987. Anti-candida drugs - the biochemical basis for their activity. Crit. Rev. Microbiol. 15:57-72.
23. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increase in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
24. Xu, L., K. Lal, R. P. Santarpia III, and J. J. Pollock. 1993. Salivary proteolysis of histidine-rich polypeptides and the anti-fungal activity of peptide degradation products. Arch. Oral Biol. 38:277-283.
25. Xu, Y., I. Ambudkar, H. Yamagishi, W. Swaim, T. J. Walsh, and B. C. O'Connell. 1999. Histatin 3-mediated killing of Candida albicans: effect of extracellular salt concentration on binding and internalization. Antimicrob. Agents Chemother. 43:2256-2262.
26. Yao, Y., M. S. Lamkin, and F. G. Oppenheim. 1999. Pellicle precursor proteins: acidic proline-rich proteins, statherin, and histatins, and their crosslinking reaction by oral transglutaminase. J. Dent. Res. 78:1696-1703.